By Doug Macron

Roche this week said it will shut down its in-house RNAi-related research activities as part of a broader cost-savings initiative that will include cutting its workforce by 6 percent over the next two years.

The company, which had been one of a handful of big pharmas to invest heavily in RNAi as a therapeutic modality, said it is responding to "mounting cost pressures in healthcare" and to "increasing hurdles for the approval and pricing of new medicines."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.